Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2453 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
	Addiess	
Fax Number:		Fax Number:
Bevacizumab		
Patient has locally advanced and Patient has preserved liver for Patient has preserved liver for Patient has not received funde or Patient received funde or Patient has exp and No disease program and To be given in combination or	ith bevacizumab, and met all remaining criteria prior to dor metastatic, unresectable hepatocellular carcinom unction (Child-Pugh A) ation (TACE) is unsuitable ed prior systemic therapy for the treatment of hepatoced lenvatinib before 1 March 2025 erienced treatment-limiting toxicity from treatment with gression since initiation of lenvatinib	a cellular carcinoma
Renewal — unresectable hepatocellular carcin Current approval Number (if known):		
Applications from any relevant practitioner. Approx Prerequisites(tick box where appropriate)		
There is no evidence of disease progres:	sion	

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2453 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Bevacizumab - continued			
Initial application — advanced or metastatic ov Applications from any relevant practitioner. Approx Prerequisites(tick boxes where appropriate)			
The patient has FIGO Stage	IV epithelial ovarian, fallopian tube, or primary perito	oneal cancer	
The patient has previo	ously untreated advanced (FIGO Stage IIIB or IIIC) ep	oithelial ovarian, fallopian tube, or primary	
	ery is inappropriate		
or The cancer is sub-optimally debulked (maximum diameter of any gross residual disease greater than 1cm)			
	ab optimizing dobumou (maximum alasmoto) of all you	35 ToSidual diocaso groater triair . s,	
and Bevacizumab to be administered a	at a maximum dose of 15 mg/kg every three weeks		
and			
18 weeks concurrent treatment wit	n cnemotnerapy is pianned		
Renewal — advanced or metastatic ovarian car	ncer		
Current approval Number (if known):			
Applications from any relevant practitioner. Approv Prerequisites (tick box where appropriate)	als valid for 4 months.		
There is no evidence of disease progress	sion		
Initial application — Recurrent Respiratory Pag	:III a materia		
Applications from any relevant practitioner. Approv			
Prerequisites(tick boxes where appropriate)			
Maximum of 6 doses			
The patient has recurrent respirator	ory papillomatosis		
and The treatment is for intra-lesional a	administration		
Renewal — Recurrent Respiratory Papillomator			
Current approval Number (if known): Applications from any relevant practitioner. Approv			
Prerequisites(tick boxes where appropriate)			
Maximum of 6 doses			
The treatment is for intra-lesional a	administration		
There has been a reduction in sur	gical treatments or disease regrowth as a result of tre	atment	

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2453 November 2025

I confirm the above details are correct and that in signing this form I understand I may be audited.